Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Deep Value
  3. /Chemicals - Others
MomentumDeep Value

Which Chemicals - Others Stocks Are Deep Value Picks in Week of May 10, 2026?

ACCEL

In the Week of May 10, 2026, the Chemicals - Others sector has 1 stocks that are underperforming Nifty 500 but have accelerating quarterly earnings. Average value score is 49/100 with PAT acceleration of +165pp.

Total Stocks
1
deep value
Avg Fundamental
49
/100
Top Pick
S
Score: 56/100
Avg Margin of Safety
Undervalued

Stock Distribution

0 Strong0 Good1 Average0 Weak

Earnings & Valuation Signals

⚠️

1 stock flagged for margin pressure — profits may not sustain.

💰

1 of 1 stock trading below fair value — sector offers value opportunities.

📊

Operating margins volatile across 1 stock — earnings quality uneven, watch for stabilization.

AI Research Summary

Sector Pulse

The 'Chemicals - Others' sub-sector is currently navigating a highly constrained operating environment, characterized by severe margin compression and mixed demand signals. Across the 3 constituents analyzed, profitability has taken a material hit. PCCL saw its operating profit plummet by 89% year-on-year, while CAMLINFINE and SHK both reported margin contraction due to raw material inventory lags, fixed cost under-absorption, and front-ended operating expenses. The demand environment remains MIXED, with 3 of 3 constituents citing headwinds ranging from European geopolitical softness to intense local competition in India.

Catalysts Playing Out Across the Pack

Despite the near-term gloom, managements are pointing to specific structural unlocks. The primary driver is Regulatory Approval Or License Win. CAMLINFINE is actively holding back 400 tons of Vanillin inventory to capitalize on a US import tariff reduction from 50% to 25%, which is expected to boost realizations to $14-14.5/kg. Meanwhile, PCCL's entire growth trajectory hinges on an NGT appeal to overturn a CAQM ban on capacity augmentation. Additionally, Operating Leverage Inflection is a shared theme; CAMLINFINE expects production costs to drop to $8/kg as Vanillin volumes scale to 4,000 tons, and SHK is targeting a 400 bps margin expansion to 17% as new factories come online.

What Managements Are Guiding

Forward guidance reflects a dichotomy between near-term pain and long-term optimism. SHK lowered its short-term EBITDA margin guidance from 15% to 13% due to high insurance costs and growth-led investments, but reaffirmed its 12% revenue CAGR target. CAMLINFINE met its revised ₹2,000-2,100 Cr FY26 revenue guidance and raised its FY27 outlook to ₹2,200 Cr. Capex remains a priority, with SHK committing ₹110-120 crore over the next 12-18 months and CAMLINFINE guiding for ₹40-50 crore, indicating that managements are looking past current cyclical troughs.

Sub-Sector Aggregates

The quantitative aggregates underscore the sector's current profitability crisis. The EBITDA Margin Range sits at a depressed 4.89% to 13.0%, with 2 of 3 constituents (PCCL and CAMLINFINE) reporting margins below 10%. This compression is largely driven by the inability to pass on costs swiftly and the burden of older, expensive raw material inventory. Despite these compressed margins, Capex Commitments range from ₹40 Cr to ₹120 Cr, showing that balance sheets are being stretched to fund future growth and geographical expansion.

Shared Risks (9-type taxonomy)

The sector is heavily exposed to commodity and regulatory risks. All 3 constituents flagged commodity-related pressures: CAMLINFINE faces falling global prices for core antioxidants, SHK is battling a time lag in passing through lower raw material costs, and PCCL is constrained by a national import ceiling on Raw Petroleum Coke. Regulatory risks are equally severe, with PCCL's expansion halted by environmental boards and CAMLINFINE's realizations dependent on the final signing of the US-India trade treaty. Furthermore, litigation risk materialized sharply for CAMLINFINE via a massive fire in Brazil, resulting in a ₹33 Cr book value loss.

Bottom Line

The sector is currently in a transition phase, absorbing high raw material costs and regulatory hurdles while investing heavily in future capacity. While the near-term margin profile is weak, the active playout of regulatory tariff cuts and impending operating leverage provide a clear line of sight to profitability recovery in FY27.

Last updated Apr 19, 2026

1 stocks in this sector

View:
Average49/100

S H Kelkar & Company Ltd

2.1K CrAccel
Deeply Undervalued
Earnings Pulse
PAT YoY
+83%
Stable
Revenue YoY
+8%
Momentum
Accelerating
▲
Margin Pressure

Explore More

All Deep Value SectorsMomentum Sectors← Back to Dashboard

Frequently Asked Questions: Chemicals - Others

Based on publicly available financial data. This is educational research, not investment advice.

How many Chemicals - Others stocks are deep value opportunities worth studying?

There are currently 1 stocks in the Chemicals - Others sector that qualify as deep value opportunities worth studying. These stocks are underperforming the market despite showing improving earnings — a classic contrarian research signal.

Which Chemicals - Others deep value stocks appear most undervalued?

The most undervalued Chemicals - Others deep value stocks based on fair value analysis

  • S H Kelkar & Company Ltd — Significantly Undervalued
  • Stocks sorted by valuation signal (most undervalued first).

Which Chemicals - Others deep value stock has the highest earnings acceleration?

Chemicals - Others deep value stocks with the highest earnings growth

  • S H Kelkar & Company Ltd — PAT growth +83.3% YoY, earnings stable

Why are Chemicals - Others stocks underperforming despite improving earnings?

Chemicals - Others deep value stocks are underperforming despite improving earnings because the market has not yet recognized their earnings recovery. This creates a potential opportunity for patient investors

  • The market often takes 2-4 quarters to re-rate stocks after earnings improve
  • Deep value stocks typically have a negative narrative that suppresses sentiment
  • Improving earnings combined with market underperformance creates a valuation gap
  • When the market eventually recognizes the recovery, re-rating can be significant
  • This is an educational explanation of deep value investing theory.

Which Chemicals - Others deep value stocks have the highest revenue growth?

Chemicals - Others deep value stocks with the highest revenue growth

  • S H Kelkar & Company Ltd — Revenue growth +7.6% YoY

What is the average PE ratio of Chemicals - Others deep value stocks?

The average PE ratio of Chemicals - Others deep value stocks is 21.9x. Deep value stocks typically trade at lower PE multiples relative to their sector peers, reflecting the market's skepticism about their recovery.

Is the earnings recovery in Chemicals - Others sustainable?

Sustainability indicators for the Chemicals - Others deep value earnings recovery

  • A sustainable recovery shows more stocks accelerating than decelerating.

Is Chemicals - Others a contrarian opportunity worth studying?

Chemicals - Others as a contrarian opportunity — key research signals

  • 1 stocks underperforming the market (contrarian setup)
  • 1 stocks appear undervalued based on fair value analysis
  • Contrarian investing requires patience.

What is the typical recovery timeline for deep value stocks?

Deep value stock recovery timelines vary, but historical patterns suggest

  • 1-2 quarters: Earnings inflection detected, market still skeptical
  • 2-4 quarters: Consistent earnings improvement builds confidence
  • 4-6 quarters: Market re-rates, stock price catches up to fundamentals
  • Some stocks never recover — continuous monitoring is essential
  • Timelines are approximate and based on historical patterns.

What is deep value investing?

Deep value investing is a strategy of studying stocks that are underperforming the market despite showing improving fundamentals (earnings growth, margin expansion). The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap.

  • These stocks typically underperform indices like Nifty 500
  • They show positive earnings trends (PAT growth, revenue growth)
  • The market eventually re-rates them as earnings improvements sustain
  • It requires patience — recovery can take several quarters

The above FAQs are based on publicly available financial data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.